Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 8, 1998, Pages 2651-2658

  Levine, Mark N ^a   Bramwell, Vivian H ^b   Pritchard, Kathleen I ^b   Norris, Brian D ^b   Shepherd, Lois E ^b   Abu Zahra, Hakam ^b   Findlay, Brian ^b   Warr, David ^b   Bowman, David ^b   Myles, Jamie ^b   Arnold, Andrew ^b   Vandenberg, Ted ^b   MacKenzie, Robert ^b   Robert, Jean ^b   Ottaway, Jon ^b   Burnell, Margot ^b   Williams, Chris K ^b   Tu, Dongsheng ^b  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031927983     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.8.2651     Document Type: Article

References (39)

1. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:71-75, 1992
2. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976
3. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with six months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
4. Moliterni A, Bonadonna G, Valagussa P, et al: Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9:1124-1130, 1991
5. Coombes RC, Bliss JM, Wils J. et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. J Clin Oncol 14:35-45, 1996
6. Carpenter JT, Velez-Garcia E, Aron BS, et al: Five-year results of a randomized comparison of cyclophosphamide, doxorubicin, and fluorouracil versus cyclophosphamide, methotrexate, and fluorouracil for node-positive breast cancer. Proc Am Soc Clin Oncol 13:68, 1994 (abstr)
7. Levine MN, Bramwell V, Pritchard K, et al: A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node-positive or locally advanced breast cancer. Eur J Cancer 29:37-43, 1993
8. Henderson IC: Chemotherapy for metastatic disease, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases. Philadelphia, PA, Lippincott, 1991, pp 604-611
9. Torti FM, Bristow MM, Lum BL, et al: Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy. Cancer Res 46:3722-3727, 1986
10. Kirti K, Casper ES, Geller N, et al: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3:818-826, 1985
11. Italian Multicentre Trial: A phase II randomized study of fluorouracil, epirubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer. J Clin Oncol 6:976-982, 1988
12. French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6:679-688, 1988
13. Hryniuk WH, Levine MN: Analysis of dose-intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
14. The Ludwig Breast Cancer Study Group: Combination adjuvant chemotherapy for node positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 319:677-683, 1988
15. Levine MN, Guyatt GH, Gent M, et al: Quality of life in stage II breast cancer: An instrument for clinical trials. J Clin Oncol 6:1798-1810, 1988
16. Brundage M, Pater J, Zee B: Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 85:1138-1148, 1993
17. Levine M, Bramwell V, Bowman D, et al: A clinical trial of intensive CEF versus CMF in premenopausal women with node-positive breast cancer. Proc Am Soc Clin Oncol 14:112, 1995 (abstr)
18. Kaplan E, Meier P: Nonparametric estimations from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977
20. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-202, 1972
21. Therneau TM, Grambsch PM, Fleming TR: Martingale-based residuals for survival models. Biometrika 77:147-160, 1990
22. Fisher RA: Statistical Methods for Research Workers (ed 14). New York, NY, Hafner, 1970, pp 76-96
23. Kleinbaum KG, Kupper LI: Applied Regression Analysis and Other Multi-Variable Methods. North Scituate, MA, Duxbury Press, 1978, pp 315-350
24. Meyer RM, Browman GP, Samosh ML, et al: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 13:2386-2393, 1995
25. Bull J, Tormey D, Li SH, et al: A randomized comparative trial of Adriamycin versus methotrexate in combination drug therapy. Cancer 41:1649-1657, 1978
26. Aisner J, Weinberg V, Perloff M, et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFP v CMF each ± MER) for metastatic breast carcinoma of the breast. A CALGB study. J Clin Oncol 5:1523-1533, 1987
27. Perloff M, North L, Korzun A, et al: Advantage of an Adriamycin combination plus halotestin after initial cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone for adjuvant therapy of node positive stage II breast cancer. Proc Am Soc Clin Oncol 5:273, 1986 (abstr)
28. Mathe G, Plagne R, Morice V, et al for the OncoFrance Breast Cancer Trial Group: Consistencies and variations of observations during serial analyses of a trial of adjuvant chemotherapy in breast cancer, in Salmon SE, Jones SE (eds): Adjuvant Therapy of Cancer V. New York, NY, Grune & Stratton, 1987, pp 271-280
29. Fisher B, Redmond C, Wickerham DL, et al: Doxorubicin-containing regimens for the treatment of stage II breast cancer: The NSABP experience. J Clin Oncol 7:572-282, 1989
30. Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, et al: Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11 q23 therapy with 4epi-doxorubicin and cisplatinum or cyclophosphamide for breast cancer. J Clin Oncol 10:1444-1451, 1992
31. Valagussa P, Moliterni A, Terenziani M, et al: Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol 5:803-808, 1994
32. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 273:542-547, 1995
33. Budd GT, Green S, O'Bryan R, et al: Short-course FAC-M versus 1 year of CMFVP in node positive, hormone receptor-negative breast cancer: An Intergroup study. J Clin Oncol 13:831-839, 1995
34. DeCillis A, Anderson S, Bryant J, et al: Acute myeloid leukemia and myelodysplastic syndrome in NSABP B25. Proc Am Soc Clin Oncol 16:459, 1997 (abstr)
35. Plosker GL, Faulds D: Epirubicin: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cancer chemotherapy. Drugs 45:788-856, 1993
36. Coukall AJ, Faulds D: Epirubicin: An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic-efficacy in the management of breast cancer. Drugs 53:453-482, 1997
37. Bonadonna G, Gianni L, Santoro, et al: Drugs ten years later: Epirubicin. Ann Oncol 4:359-369, 1993
38. Nielson D, Jensen JB, Dombernowsky P, et al: Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer. J Clin Oncol 8:1806-1810, 1990
39. Wood WC, Budman DR, Korzun AH, et al: Dose and dose-intensity of adjuvant chemotherapy for stage II node-positive breast cancer. N Engl J Med 330:1253-1259, 1994